Search clinical trials for: A/H1N1 vaccine

Total 472722 results

PHAC/CIHR Influenza Research Network
GlaxoSmithKline; CHU de Quebec-Universite Laval; The Ottawa Hospital; Hamilton... and other collaborators

Completed

Surveillance for Adverse Events Following Pandemic H1N1 Immunization

Novel Influenza A/H1N1
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

H1N1v Virus Challenge Study in Healthy Subjects

Influenza

United States
Butantan Institute
University of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...

Completed

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Immunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)Vaccine

Brazil
Instituto Nacional de Salud Publica, Mexico
Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.

Withdrawn

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Influenza

Mexico
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
University Health Network, Toronto

Unknown

Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

Influenza

Canada
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
Novavax
Instituto Mexicano del Seguro Social

Completed

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Seasonal Influenza

Mexico
The University of Hong Kong
Queen Elizabeth Hospital, Hong Kong; Queen Mary Hospital, Hong Kong; Pamela Youde... and other collaborators

Completed

H-IVIG Treatment for Severe H1N1 2009

Novel 2009 Influenza A (H1N1) Infection

Hong Kong
Opera CRO, a TIGERMED Group Company

Completed

Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects

Influenza

Italy
AVIR Green Hills Biotechnology AG

Completed

Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers (GHBCS-01)

Seasonal Human Influenza

Austria
French National Agency for Research on AIDS and...
GlaxoSmithKline

Completed

Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

HIV Infections

France
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

H1N1 Influenza Virus

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India

Influenza | Pandemic Influenza | Influenza A Virus, H1N1 Subtype

India
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People

Influenza

United States
Finnish Institute for Health and Welfare

Completed

Evaluation of Pandemic Vaccination Campaign

Influenza Caused by the Novel A(H1N1)v Influenza Virus

Finland
University of Rochester

Completed

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

Influenza

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
Hutchison Whampoa Guangzhou Baiyunshan Chinese...
Guangzhou Institute of Respiratory Disease

Unknown

Banlangen Granules Anti-seasonal Influenza Study (BLG)

Influenza

China
Leiden University Medical Center
Erasmus Medical Center

Completed

Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza (RICH-3)

HIV

Netherlands
Novartis Vaccines

Completed

Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine

Influenza A (H1N1)

Italy
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 + TIV - Adults and Elderly

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

Influenza | Swine-origin A/H1N1 Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
MedImmune LLC
Department of Health and Human Services

Completed

A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age (MI-CP217)

Influenza

United States
Erasme University Hospital

Completed

Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients

Influenza | Rejection | Decreased Immunologic Activity [PE]

Belgium

Search clinical trials for: A/H1N1 vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations